Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 17/20 | 0.69 |
| ▸ | CHUK | O15111 | 8/20 | 0.69 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | PRKCG | P05129 | 1/20 | 0.61 |
| ▸ | PRKCB | P05771 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | PRKCA | P17252 | 1/20 | 0.61 |
| ▸ | PRKCH | P24723 | 1/20 | 0.61 |
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.61 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.61 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.61 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.61 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.61 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.59 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.59 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8140829 | 0.99 | IKBKB (0.68) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL8146801 | 0.83 | ZAP70 (0.59) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL8154028 | 0.83 | ZAP70 (0.62) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL8139875 | 0.83 | ZAP70 (0.62) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL6956423 | 0.82 | ZAP70 (0.68) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL6955195 | 0.81 | ZAP70 (0.67) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL8148275 | 0.81 | ZAP70 (0.62) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL6951420 | 0.80 | ZAP70 (0.66) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL6950853 | 0.80 | ZAP70 (0.66) | IKBKBCHUKZAP70PRKD3EGFR | |
| SCHEMBL6955286 | 0.80 | ZAP70 (0.66) | IKBKBCHUKZAP70PRKD3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005037259-A2 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF NEOPLASIA COMPRISING A COX-2 INHIBITOR IN COMBINATION WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | US | claimed |
| US-6093716-A | Substituted 2-pyrimidineamines and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-07-25 | — | — | US | claimed |
| EP-0929549-A1 | SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-21 | — | — | EP | claimed |
| WO-1998011095-A1 | SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-03-19 | — | — | WO | claimed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| CN-104174071-A | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIODEVICE INTERNAT GMBH | 2014-12-03 | — | — | CN | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| WO-2005018683-A2 | ANASTOMOTIC CONNECTOR DEVICES | ANGIOTECH INTERNATIONAL AG (CH) | 2005-03-03 | — | — | WO | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060405-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-6093716-A | Substituted 2-pyrimidineamines and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| EP-0929549-A1 | SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998011095-A1 | SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | EGFR, PTGFR, ERBB2 | IKBKB 143/4885CHUK 37/4885ZAP70 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.